<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286750</url>
  </required_header>
  <id_info>
    <org_study_id>ID-086-102</org_study_id>
    <secondary_id>2019-004262-17</secondary_id>
    <nct_id>NCT04286750</nct_id>
  </id_info>
  <brief_title>Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-ascending Doses of ACT-1004-1239 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study in healthy subjects to examine the safety and tolerability of ACT-1004-1239 given as
      multiple, gradually increasing doses and to examine the effects of ACT-1004-1239 on the body
      and the way the body takes up, distributes, and gets rid of ACT-1004-1239
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 11, 2020</start_date>
  <completion_date type="Anticipated">December 16, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent (serious) adverse events</measure>
    <time_frame>From first study treatment administration up to End of Study (EOS). Duration: up to 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ACT-1004-1239 Dose level 1 (30 mg) to 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-1004-1239</intervention_name>
    <description>ACT-1004-1239 administered as hard capsules for oral use.</description>
    <arm_group_label>ACT-1004-1239 Dose level 1 (30 mg) to 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo administered as hard capsules for oral use.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure.

          -  Healthy male or female subject aged between 18 and 55 years (inclusive) at Screening.

          -  A female subject of childbearing potential must have a negative serum pregnancy test
             at Screening and a negative urine pregnancy test on Day - 1 and must agree to
             consistently and correctly use a highly effective method of contraception with a
             failure rate of ≤1% per year, be sexually inactive, or have a vasectomized partner.

          -  A female subject of non-childbearing potential must be postmenopausal, or must have a
             medical history of previous bilateral salpingectomy, bilateral salpingo-oophorectomy,
             hysterectomy, premature ovarian failure, XY genotype, Turner syndrome, or uterine
             agenesis.

          -  A male subject must use adequate contraception from first study treatment
             administration up to at least 90 days after last administration unless he is
             vasectomized.

          -  A male subject must agree to refrain from donation of semen from first study treatment
             administration up to at least 90 days after last administration.

        Exclusion Criteria:

          -  Previous exposure to ACT-1004-1239.

          -  Known hypersensitivity to ACT-1004-1239, or any of its excipients.

          -  History of major medical or surgical disorders which, in the opinion of the
             investigator, are likely to interfere with the absorption, distribution, metabolism,
             or excretion of the study treatment.

          -  Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the
             evaluation of the study.

          -  Previous treatment with any prescribed medications (including vaccines) or
             over-the-counter (OTC) medications (including herbal medicines such as St John's Wort,
             homeopathic preparations, vitamins, and minerals) within 3 weeks prior to first study
             treatment administration.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.

          -  Pregnant or lactating woman.

          -  Any cardiac condition or illness that may jeopardize the safety of the study subject
             per investigator judgment based on medical history or 12-lead ECG measured at
             Screening.

          -  Any immunosuppressive treatment within 6 weeks or 5x terminal half-life (t½),
             whichever is longer, before study treatment administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Disclosure Desk</last_name>
    <phone>+41 58 844 1977</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BlueClinical Phase 1 Hospital de Prelado</name>
      <address>
        <city>Porto</city>
        <zip>4250-449</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

